Status:
COMPLETED
Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip
Lead Sponsor:
Laboratoires NEGMA
Conditions:
Hip Osteoarthritis
Eligibility:
All Genders
50-75 years
Phase:
PHASE3
Brief Summary
We carried out a 3 years, randomized, double-blind, placebo-controlled, multicenter clinical trial in patients with hip osteoarthritis in order to: * evaluate the ability of diacerein, an interleukin...
Eligibility Criteria
Inclusion
- Outpatients fulfilling the American College of Rheumatology criteria for the diagnosis of hip osteoarthritis.
- Lequesne algofunctional index of at list 3 points.
- Radiographic criterion for inclusion: joint space width (JSW) between 1 mm and 3 mm. If the JSW exceeded 3 mm, it had to be at least 0.5 mm thinner than JSW of the contra lateral hip, measured at its narrowest point.
Exclusion
- Intraarticular injection or arthroscopy of the hip during the three months prior to inclusion in the study.
- Any systemic or intraarticular corticosteroid as well as other potential symptom-modifying drugs for osteoarthritis were not allowed during the study.
Key Trial Info
Start Date :
March 1 1993
Trial Type :
INTERVENTIONAL
End Date :
April 1 1997
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00451360
Start Date
March 1 1993
End Date
April 1 1997
Last Update
July 25 2008
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Nord
Amiens, France, 80030
2
Hôpital Pellegrin
Bordeaux, France, 33076
3
Hôpital Ambroise Paré
Boulogne, France, 92100
4
CHU cote de Nacre
Caen, France, 14033